Soleno Therapeutics Reports Strong Preliminary Q4 & Full-Year 2025 Results, Achieves Profitability
Summary
Soleno Therapeutics reported strong preliminary Q4 and full-year 2025 results, achieving profitability and positive cash flow driven by the successful launch of VYKAT XR.
Key Events
-
Achieved Profitability and Positive Cash Flow
The company announced it has achieved profitability and positive cash flow, a critical financial milestone following the successful launch of VYKAT XR.
-
Strong VYKAT XR Sales and Market Penetration
Preliminary full-year 2025 net revenue from U.S. VYKAT XR sales is expected to be $189-$191 million, with 1,250 new patient start forms representing approximately 12.5% of the addressable U.S. market.
-
Robust Cash Position
Soleno ended 2025 with approximately $500 million in cash, cash equivalents, and marketable securities, even after a $100 million accelerated share repurchase program.
-
Broad Insurance Coverage and Prescriber Growth
VYKAT XR now has over 185 million lives covered (approximately 60% of total lives) and has seen 630 unique prescribers since launch.
Analysis
Soleno Therapeutics announced robust preliminary financial and operational results for Q4 and full-year 2025, highlighted by the successful commercialization of VYKAT XR. The company achieved profitability and positive cash flow, a significant milestone for a biopharmaceutical firm. Strong patient uptake and broad insurance coverage for VYKAT XR underscore its market acceptance and potential for continued growth. This financial strength, coupled with a substantial cash reserve, positions Soleno well for future development and market expansion.
At the time of this filing, SLNO was trading at $44.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $41.50 to $90.32. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.